as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹96.98
Change
+0.48 (0.5%)
Open
₹96.92
Prev. Close
₹96.5
Day High
₹98.0
Day Low
₹96.2
Volume Analysis
Traded
19,850
Delivered
13,444
Delivery %
67.73%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (0.41%)
- •Below-average fundamentals quality score (39/100)
- •Low operating margin (-13.0%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹99.72 | ₹98.86 | ₹97.92 | ₹97.06 | ₹96.12 | ₹95.26 | ₹94.32 |
| Fibonacci | ₹98.86 | ₹98.17 | ₹97.75 | ₹97.06 | ₹96.37 | ₹95.95 | ₹95.26 |
| Camarilla | ₹97.48 | ₹97.31 | ₹97.15 | ₹97.06 | ₹96.82 | ₹96.65 | ₹96.49 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-2.85%
1 Week
-4.98%
1 Month
+1.14%
3 Months
-8.63%
6 Months
-3.3%
1 Year
-13.8%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹10.81
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.3%
Net margin 12.05% × asset turnover 0.57x × equity multiplier 1.5x
Company Overview
Sector
Healthcare
Market Cap
₹929 Cr
P/E (TTM)
624.0
ROE
0.41%
Book Value
₹43.3
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Themis Medicare Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 39/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (0.41%); below-average fundamentals quality score (39/100).
TopFund Score — Fundamentals Quality
39/100 — WeakData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 143%
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 8.21% over past five years.
- −Company has a low return on equity of 6.41% over last 3 years.
- −Promoters have pledged 45.8% of their holding.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Board approved unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 97 | 105 | 83 | 98 | 123 | 117 | 94 | 72 | 98 | 78 | 90 | 77 | 87 |
| Expenses + | 75 | 92 | 74 | 89 | 94 | 100 | 88 | 79 | 108 | 81 | 80 | 73 | 139 |
| Operating Profit | 22 | 12 | 8 | 9 | 29 | 17 | 6 | -8 | -10 | -3 | 10 | 4 | -52 |
| OPM % | 22.0% | 12.0% | 10.0% | 10.0% | 24.0% | 15.0% | 6.0% | -11.0% | -10.0% | -4.0% | 11.0% | 4.9% | -60.0% |
| Other Income + | 6 | 7 | 6 | 5 | 7 | 6 | 1 | 2 | 1 | 5 | 6 | 11 | 97 |
| Interest | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 23 | 14 | 8 | 9 | 31 | 18 | 2 | -11 | -14 | -3 | 10 | 9 | 39 |
| Tax % | 19.0% | 19.0% | 10.0% | 24.0% | 21.0% | 20.0% | 69.0% | -13.0% | 1.0% | 5.0% | 3.0% | 2.0% | 36.0% |
| Net Profit + | 18 | 11 | 7 | 7 | 25 | 14 | 1 | -10 | -14 | -4 | 10 | 9 | 25 |
| EPS in Rs | 2 | 1 | 1 | 1 | 3 | 2 | 0 | -1 | -2 | 0 | 1 | 1 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 2 | 15 | -7 | 22 | 27 | 12 | 14 | -27 | -21 | -33 | -4 | 7 | -11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 202 | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 406 | 342 | 332 |
| Expenses + | 184 | 194 | 184 | 184 | 181 | 166 | 181 | 299 | 287 | 330 | 356 | 342 | 374 |
| Operating Profit | 18 | 38 | 33 | 25 | 2 | 36 | 49 | 96 | 67 | 52 | 49 | 0 | -42 |
| OPM % | 9.0% | 16.0% | 15.0% | 12.0% | 1.2% | 18.0% | 21.0% | 24.0% | 19.0% | 13.0% | 12.0% | 0.1% | -13.0% |
| Other Income + | 13 | 3 | 4 | 6 | 5 | 12 | 13 | 18 | 25 | 24 | 11 | 23 | 118 |
| Interest | 15 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 | 10 | 11 | 11 |
| Depreciation | 11 | 12 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 | 10 | 10 | 10 |
| Profit before tax | 5 | 17 | 18 | 11 | -13 | 27 | 41 | 95 | 73 | 53 | 40 | 2 | 55 |
| Tax % | -20.0% | 11.0% | 9.0% | 1.0% | -15.0% | 8.0% | 14.0% | 23.0% | 22.0% | 19.0% | 25.0% | 40.0% | — |
| Net Profit + | 6 | 16 | 16 | 11 | -11 | 25 | 36 | 73 | 57 | 44 | 30 | 1 | 40 |
| EPS in Rs | 1 | 2 | 2 | 1 | -1 | 3 | 4 | 8 | 6 | 5 | 3 | 0 | 4 |
| Dividend Payout % | 25.0% | 9.0% | 0.0% | 0.0% | 0.0% | 6.0% | 11.0% | 6.0% | 8.0% | 11.0% | 15.0% | 404.0% | — |
| Sales growth | 4 | 15 | -7 | -3 | -12 | 10 | 14 | 71 | -10 | 8 | 6 | -16 | -13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 51 | 66 | 143 | 160 | 149 | 174 | 209 | 278 | 330 | 368 | 393 | 389 |
| Borrowings + | 140 | 128 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 96 | 83 | 100 |
| Other Liabilities + | 77 | 73 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 93 | 102 | 99 |
| Total Liabilities | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 598 |
| Fixed Assets + | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 172 | 167 |
| CWIP | 4 | 6 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 | 3 | 2 |
| Investments | 5 | 6 | 23 | 24 | 27 | 35 | 45 | 56 | 70 | 89 | 95 | 109 |
| Other Assets + | 146 | 146 | 133 | 153 | 162 | 191 | 191 | 225 | 279 | 307 | 318 | 320 |
| Total Assets | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 598 |
| Equity Capital | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 26 | -2 | 8 | 11 | 0 | 57 | 34 | 16 | 22 | 35 | -3 |
| Cash from Investing Activity + | -6 | -7 | -4 | 0 | -4 | -5 | -16 | -16 | -24 | -16 | -12 | -3 |
| Cash from Financing Activity + | -18 | -13 | 5 | -9 | -10 | 7 | -26 | -18 | 0 | -9 | -26 | 4 |
| Net Cash Flow | -5 | 5 | 0 | -1 | -3 | 2 | 16 | 1 | -8 | -3 | -3 | -2 |
| Free Cash Flow | 13 | 18 | -7 | 5 | 5 | -5 | 39 | 15 | -13 | 4 | 21 | -8 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 101 | 73 | -5 | 29 | 490 | 2 | 115 | 55 | 48 | 60 | 93 | 782 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 32.82% | 32.81% | 32.79% | 32.74% | 32.75% | 32.7% | 32.75% | 32.77% | 32.84% | 32.78% | 32.87% | 32.87% |
| Promoters | 67.16% | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.1% | 67.1% | 67.1% | 67.1% |
| FII | 0.01% | 0.03% | 0.05% | 0.1% | 0.1% | 0.14% | 0.09% | 0.06% | 0.05% | 0.11% | 0.01% | 0.01% |
| DII | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Themis Medicare Ltd. (this stock) | 929 | 624.0 | 2.33 | 0.41% |
| Health X Platform Limited | 862 | 510.0 | 1.36 | 0.44% |
| Lincoln Pharma Ltd | 1,032 | 10.6 | 1.27 | 12.0% |
| Kilitch Drugs India Ltd | 805 | 33.4 | 2.79 | 10.6% |
| Shree Ganesh Remedies Ltd | 798 | 65.9 | 4.79 | 10.8% |
| Laxmi Dental Limited | 1,076 | 29.7 | 4.05 | 14.8% |
| Sigachi Industries Ltd | 1,088 | 41.3 | 2.02 | 5.78% |
Which Mutual Funds Hold Themis Medicare Ltd.?
Frequently Asked Questions about Themis Medicare Ltd.
Themis Medicare Ltd. (THEMISMED) closed at ₹96.98 on NSE on 19 November 2026, up 0.48 (0.5%) from the previous close.
Themis Medicare Ltd. trades on the NSE (National Stock Exchange of India) under the symbol THEMISMED.
Themis Medicare Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 624.0.
Themis Medicare Ltd. has a dividend yield of 0.5%.
Themis Medicare Ltd.'s 52-week high is ₹141.0 and its 52-week low is ₹65.0.
Themis Medicare Ltd. has a market capitalisation of ₹929 crore.
Themis Medicare Ltd. has a TopFund Quality Score of 39/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Themis Medicare Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.